Kymera Therapeutics, Inc. (KYMR) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$137.54

From 52W high−5.97%

Volume1.71M

Market cap$10.94B

P/E (TTM)—

P/S (TTM)107.0x

Div yield—

Key dataNov 5, 2026

Open

$137.54

From 52W high

−5.97%

Volume

1.71M

Market cap

$10.94B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−29.4x

P/E (TTM)

—

RSI (14)

61.4

MomentumView details →

1D Return

−5.97%

YTD Return

+63.90%

SummaryUpdated Sep 1, 2026

Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in August 2020 and has emerged as a pioneer in the field of targeted protein degradation, a novel therapeutic approach that harnesses the body's natural cellular machinery to eliminate disease-causing proteins. Since its inception, Kymera has built a robust pipeline of small molecule protein degraders targeting both oncology and immunology indications, with multiple programs advancing through clinical trials and a strategic partnership with Sanofi for its lead IRAK4 program.

Ask drillr about Kymera Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−29.4x

EV/Sales

98.2x

P/S (TTM)

107.0x

P/B (TTM)

6.8x

ProfitabilityView details →

Gross Margin

174.52%

Net Margin

−341.87%

EBITDA Margin

−333.89%

ROE (TTM)

−21.65%

ROA (TTM)

−19.77%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

+133.74%

EPS YoY

−1.11%

FCF YoY

−25.49%

Revenue CAGR 3Y

−5.75%

EPS CAGR 3Y

−23.83%

EBITDA YoY

−19.09%

MomentumView details →

1D Return

−5.97%

YTD Return

+63.90%

1Y Return

+109.07%

RSI (14)

61.4

vs 50D SMA

+10.49%

vs 200D SMA

+30.65%

Capital & dividendView details →

Debt/Equity

0.05x

Current Ratio

11.13x

Quick Ratio

11.13x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.32

EPS Surprise

−4.76%

Beats (12Q)

7/12

Next Q EPS Est

−$1.29

Avg Surprise (4Q)

−1.37%

Rev Surprise

−58.79%

Financials snapshotView financials →

Revenue (TTM)

102.22M

Net Income (TTM)

−349.47M

Op. CF (TTM)

−287.56M

Next earningsFeb 25, 2027 →

Latest newsMore news →

Kymera Therapeutics, Inc. plans to announce mid-stage clinical trial data for its lead asset KT-621 in eczema before the end of 2026.4d ago

Kymera Therapeutics, Inc. reported positive Phase 1 healthy-volunteer results for KT-579, showing deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile.8d ago

Similar companies

BioMarin Pharmaceutical Inc.BMRN Summit Therapeutics Inc.SMMT 欧林生物688319.SH Bio-Techne CorporationTECH Ascentage Pharma Group International06855.HK Apogee Therapeutics, Inc.APGE Find similar companies →

Latest newsMore news →

Kymera Therapeutics, Inc. plans to announce mid-stage clinical trial data for its lead asset KT-621 in eczema before the end of 2026.4d ago Kymera Therapeutics, Inc. reported positive Phase 1 healthy-volunteer results for KT-579, showing deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile.8d ago Kymera Therapeutics, Inc. reported its third-quarter 2026 financial results.8d ago